Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

SYK expression level distinguishes control from BRCA1-mutated lymphocytes.

Zahavi T, Sonnenblick A, Shimshon Y, Kadouri L, Peretz T, Salmon AY, Salmon-Divon M.

Cancer Manag Res. 2018 Mar 26;10:589-598. doi: 10.2147/CMAR.S156359. eCollection 2018.

2.

Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.

Zahavi T, Yahav G, Shimshon Y, Gershanov S, Kaduri L, Sonnenblick A, Fixler D, Salmon AY, Salmon-Divon M.

Biochem Biophys Res Commun. 2016 Nov 4;480(1):36-41. doi: 10.1016/j.bbrc.2016.10.013. Epub 2016 Oct 6.

PMID:
27721065
3.

VennBLAST—whole transcriptome comparison and visualization tool.

Zahavi T, Stelzer G, Strauss L, Salmon AY, Salmon-Divon M.

Genomics. 2015 Mar;105(3):131-6. doi: 10.1016/j.ygeno.2014.12.004. Epub 2014 Dec 20.

4.

A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.

Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T.

Breast. 2014 Aug;23(4):435-8. doi: 10.1016/j.breast.2014.03.003. Epub 2014 May 14.

5.

Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.

Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.

Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.

6.

Flame burn protection: assessment of a new, air-cooled fireproof garment.

Eldad A, Salmon AY, Breiterman S, Chaouat M, BenBassat H.

Mil Med. 2003 Aug;168(8):595-9.

PMID:
12943032
7.

Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine.

Salmon AY, Goren Z, Avissar Y, Soreq H.

Clin Exp Pharmacol Physiol. 1999 Aug;26(8):596-600.

PMID:
10474772

Supplemental Content

Loading ...
Support Center